Regeneron Pharmaceuticals Inc Regeneron (NASDAQ: REGN) And Sanofi’s Dupixent Accepted For Review By FDA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) revealed on Thursday that FDA has awarded the authorization to Dupixent as an add-on cure for moderate-to-severe asthma.